U.S. markets closed

Cleveland BioLabs, Inc. (CBLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9900+0.0100 (+0.20%)
At close: 4:00PM EDT
5.0900 +0.10 (2.00%)
After hours: 06:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close4.9800
Open4.8900
Bid4.8600 x 1200
Ask5.0500 x 1200
Day's Range4.8501 - 5.0998
52 Week Range1.6200 - 10.9700
Volume162,575
Avg. Volume224,724
Market Cap77.19M
Beta (5Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.1790
Earnings DateMay 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
    PR Newswire

    Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

    Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that the Company and Cytocom Inc., a leading biopharmaceutical company developing next generation therapeutics that target immune restoration and homeostasis, will host an investor call and live webcast on Wednesday, July 7 at 8:30 a.m. ET.

  • Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC
    Benzinga

    Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC

    Cleveland BioLabs Inc (NASDAQ: CBLI) says that the SEC registration statement regarding the previously announced merger with Cytocom Inc was declared effective by the SEC on June 10. The merger is expected to close in the Q3 of 2021, subject to approval by Cleveland BioLabs' stockholders. A special meeting of the Cleveland BioLabs stockholders related to the merger will be held virtually on July 6 at 10:00 a.m. E.T. After the deal's closure, the new combined company will be named Cytocom Inc, an

  • Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement  for Previously Announced Merger Declared Effective by SEC
    PR Newswire

    Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

    Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its registration statement on SEC Form S-4 (the "Registration Statement") filed with U.S. Securities and Exchange Commission (the "SEC") in connection with its previously announced merger with Cytocom Inc. ("Cytocom") was declared effective by the SEC on June 10, 2021. Cytocom is a leading biopharmaceutical company creating next-generation immu